Premium
Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1602
Subject(s) - tofacitinib , janus kinase inhibitor , medicine , janus kinase , rheumatoid arthritis , adverse effect , pharmacology , dermatology , receptor
Tofacitinib (Xeljanz) is an oral janus kinase (JAK) inhibitor indicated for the second‐line treatment of moderate to severe active rheumatoid arthritis in adults. This article discusses its properties, efficacy and adverse effects.